Enara Bio
enarabio.com
Actively hiring
Health Care
Biotechnology
Cell & Gene Therapy
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$32.5M
1 round on record
Latest round
$32.5M
Series B · Oct 2024 · 23 mo ago
Hiring now
1
+1 posted in 30 days
Backers
2
RA Capital Management, M Ventures
The money's age
Due for its next round
23 months since the last round · and hiring
Momentum
13/100
hiring for its size
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | Oct 2024 | $32.5M | — | menafn |
Registers and programsofficial lists and records that name the company
| Legal entity | Enara Bio Limited | its site |
Founders and leadersfrom filings, registers and the company's site
Scientific AdvisorsDirectorscompany's site
Founders InvestorsDirectorscompany's site
Robert AngDirectorscompany's site
Rana Al-HallaqDirectorcompany's site
Mike DybbsDirectorcompany's site
Clive WoodDirectorcompany's site
Backed byfrom the funds' portfolios and accelerator catalogs
RA Capital Management 
M Ventures Similar startupsby what they do, their industry and backers
Adventris Pharmaceuticals is a biotechnology company focusing on cancer immunotherapy.
Cancer immunotherapy that turns cancer cells into biofactories minting their own destruction.
Creating next generation immunotherapy treatments for cancer and autoimmune disease.
Reprogramming is the next leap forward in cancer immunotherapy. Asgard Therapeutics is a Swedish private biotech company exploring direct…
Learn more about Gordian Biotechnology and our company and people.
PINPOINT DNA MEDICINES FOR CHRONIC DISEASES. Next generation precision molecular therapies to tackle, in a safe and durable way, chronic…
News
Enara Bio Presents First-in-Class DARKFOX-Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential in Solid Tumor ...
Read more
Report
Enara Bio to Unveil First-in-Class DARKFOX-Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential for Solid Tumor Immunotherapy
Oxford, UK - March 17, 2026.Enara Bio, a pioneer in Dark Antigen discovery and bispecific T cell engager innovation, today announced new data to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, highlighting its lead
Read more
Report
Enara Bio to Unveil First--in--Class DARKFOX--Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential for Solid Tumor ...
Read more
Report
Enara Bio to Reveal DARKFOX, a Novel Cancer-Specific Dark Antigen with Broad-Ranging Therapeutic Potential, in Oral Presentation at SITC 2025
Oxford, United Kingdom - October 3, 2025. Enara Bio, a biopharmaceutical company pioneering the discovery of novel Dark Antigens and the development of bispecific T cell engagers for solid tumors, will present two abstracts related to the significant ther
Read more
Report
Enara Bio Strengthens Senior Leadership with Key Executive and Board Appointments Alongside Acceleration of Multiple T-Cell Engager Programs
Stacey Davis appointed as Chief Business Officer and Chief Financial Officer Clive Wood, Ph.D. joins Enara Board as Non-executive Director Oxford, United Kingdom - May 01, 2025. Enara Bio, a biopharmaceutical company pioneering the development of bispecif
Read more
Report
Enara Bio Raises $32.5 Million Series B Financing To Advance First-In-Class Pipeline Of TCR-Based Immunotherapies Targeting Novel Dark Antigens
Read more
Report
ROME Therapeutics and Enara Bio to Host Inaugural Dark Genome Symposium Convening Industry and Academic Leaders to Catalyze Therapeutic Application of Dark Genome Research
Read more
Report
Enara Bio announces the appointment of highly experienced biotech executive Dr. Robert Ang to its Board of Directors
/PRNewswire/ -- Enara Bio, a biotechnology company advancing novel T-cell receptor (TCR) directed immunotherapies against unconventional, shared,...
Read more
Report
People
Scientific Advisors
Directors
Founders Investors
Directors
Robert Ang
Directors
Rana Al-Hallaq
Director
Mike Dybbs
Director
Clive Wood
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Growth
Hiring Momentum
28/100
Slowing
Open positions
1
0 opened / 0 closed in 30 days
ATS activity
Every ~19 hours
09/30/2026
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Science & Research
100% ▲
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Oxford
Oxford
United Kingdom
Regional office
Enara Bio
1 open roles 1 posted in 90 days 100% engineering
hires for Science & Research
1 Robert Robinson Avenue, Oxford, OX4 4GA
Financials
Total raised
$32.5M
Latest round
Series B
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series B | 2024 | $32.5M | Details |